Trial | NCT03329235  Report issue

Title

Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis
Intraosseous With Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Treatment of Knee Osteoarthritis

  • Phase

    Early Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    PRP HA

  • Study Participants

    86
The aim of this study was to compare the efficacy of treatment in three groups of patients with knee osteoarthritis (OA) given a combination of intraosseous with intra-articular injection of platelet rich plasma (PRP), intra-articular injection of PRP and a single application of hyaluronic acid (HA).
Methods Eighty-six patients from January 2015 to June 2015 with grade II to grade III knee osteoarthritis according to the Kellgren-Lawrence classification were randomly divided into 3 groups to receive either PRP or HA. Group A received intra-articular injection of PRP 2 ml combination with medial tibial plateau and medial femoral condyle injection of PRP 2 ml (once more 2 weeks later). Group B were treated with 2 ml of PRP intra-articular injection every 14 days for a total of two injections. Group C received intra-articular injection of hyaluronic acid 2 ml every 7 days for five injections. All patients were evaluated by the Visual Analogue Scale (VAS) and the Western Ontario and McMaster Universities (WOMAC) score before the treatment and at 1st, 3rd, 6th, 12th and 18th months.
Study Started
Jan 01
2015
Primary Completion
Jun 30
2015
Study Completion
Jan 01
2017
Last Update
Nov 01
2017

Drug PRP

platelet rich plasma

Drug HA

hyaluronic acid

Intra-articular injection of HA Active Comparator

injection of HA 2 ml

Intraosseous and intra-articular Experimental

injection of PRP 2 ml

intra-articular PRP Active Comparator

injection PRP 2 ml

Criteria 

Inclusion Criteria:

Unilateral symptomatic knee with pain for at least 1 month or swelling.
Radiographic findings of knee degeneration (Kellgren-Lawrence score of II - III).
Age 40-73 years.
Body mass index (BMI) 18-32.5).
Knee stability without a severe trauma history.

Exclusion Criteria:

Bilateral knee osteoarthritis indicative of treatment for both knees.
Kellgren-Lawrence score greater than III.
BMI >32.
Age >73 years.
Systemic autoimmune rheumatic diseases and blood disorders.
Active immunosuppressive or anticoagulant therapy.
Intra-articular injection to the knee within the previous 1 year or previous joint infection.
use of corticosteroids for 3 weeks before the procedure.
use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the 3 weeks before treatment.
No Results Posted